Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
0.036
USD
-12.2%
Market Closed
Market Cap:
$580k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
UK |
|
M
|
Mulia Industrindo Tbk PT
IDX:MLIA
|
ID |
|
Arbor Realty Trust Inc
NYSE:ABR
|
US |
|
P
|
Pernod Ricard SA
F:PER
|
FR |
|
STERIS plc
NYSE:STE
|
IE |
|
C
|
Credit Suisse Group AG
F:CSX
|
CH |
|
Dof ASA
OSE:DOF
|
NO |
|
C
|
Cypher Metaverse Inc
CNSX:CODE
|
CA |
|
King Wan Corp Ltd
SGX:554
|
SG |
|
G
|
G Capital PCL
SET:GCAP
|
TH |
|
National Cinemedia Inc
NASDAQ:NCMI
|
US |
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ADAP's stock price target?
Not Available
ADAP doesn't have any price targets made by Wall Street professionals.
What is Adaptimmune Therapeutics PLC's Revenue forecast?
Projected CAGR
9%
9%
For the last 11 years the
compound annual growth rate for
Adaptimmune Therapeutics PLC's revenue is
68%.
The projected
CAGR
for the next 4 years is
9%.
